# A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients

> **NCT02388594** · PHASE1 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 14 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)

## Interventions

- **DRUG:** ZFN Modified CD4+ T Cells
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02388594
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2018-09
- **Final completion:** 2019-03
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02388594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02388594, "A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02388594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*